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Candida glabrata has emerged as a common cause of serious life-threatening fungal infections, largely 
owing to their low susceptibility to azole antifungals. Recent guidance indicates the use of echinocandins 
as the first-choice drug for the treatment of systemic infections of C. glabrata; however, C. glabrata 
resistance to echinocandins is reportedly increasing. Herein, we present the induction of anidulafungin 
resistance in planktonic and sessile cells of C. glabrata and the development of fluconazole cross-
resistance. MICs of 21 clinical C. glabrata strains were determined by a broth microdilution method 
using anidulafungin and fluconazole. Biofilm formation on a tracheal catheter was determined using 
1- × 1-cm2 polyvinyl polychloride catheter fragments. Induction of anidulafungin resistance in planktonic 
and sessile cells and evaluation of its stability were performed by exposing the strains to successively 
higher concentrations of the antifungal. The induction resulted in strains strongly resistant to anidulafungin 
(MICs: 1−2 μg/mL) and fluconazole (≥64 μg/mL). Most of the sessile cells of C. glabrata presented 
slightly reduced susceptibility compared with the planktonic cells. Clinically, this cross-resistance 
could lead to therapeutic failure while using fluconazole in patients previously exposed to subinhibitory 
concentrations of anidulafungin for extended periods.
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INTRODUCTION
In recent decades, the frequency of invasive yeast 
infections has significantly increased with the increase in 
the number of patients undergoing immunosuppressive 
therapy, the use of broad-spectrum antimicrobials, and 
the frequency of organ transplants (Silva et al., 2012). 
Systemic infections caused by Candida glabrata are 
characterized by a high mortality rate and are difficult to 
treat due to reduced susceptibility to azole antifungals, 
particularly fluconazole (McCornack, Perry, 2005; 
Katiyar et al., 2012; Rodrigues, Silva, Henriques, 2014). 
This yeast can colonize host tissues and abiotic surfaces 
(catheters and prostheses) where it develops multi-
layer growth characterized as a biofilm (Katiyar et al., 
2012). 
Biofilms are communities of microorganisms 
adhering to a surface and embedded in a polymeric 
extracellular matrix (Donlan, Costerton, 2002) and 
considered the most prevalent form of growth in the 
environment they inhabit. Biofilm formation is an essential 
virulence factor for Candida species, and it confers 
significant resistance to antifungal therapy by limiting the 
penetration of substances into the matrix and protecting the 
cells against the immune response of the host (Mukherjee, 
Chandra J, 2004). 
Considering the importance of invasive mycoses 
and their current epidemiology, it is necessary to 
develop multiple therapeutic strategies. A few years ago, 
therapeutic management was performed with azoles and 
amphotericin B. However, considering the increasing 
azole resistance, mainly caused by non-albicans Candida 
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species and due to renal toxicity of amphotericin B, a new 
pharmacological group, the echinocandins, emerged as a 
novel therapeutic option (Pham et al., 2014). 
Echinocandins inhibit the 1,3-β-D-glucan synthase 
(GS) complex that catalyzes the biosynthesis of 1,3-β-D-
glucan, the primary glucan component of the fungal cell 
wall. GS, an enzyme, is complex and has at least two 
subunits: Fksp and Rho1p. Among these, Fksp, encoded 
by three paralogous genes (FKS1, FKS2, and FKS3), is the 
catalytic subunit and target of echinocandins. Resistance 
to these antifungal agents, resulting in therapeutic failure, 
has been linked to mutations in the Fksp subunit of GS 
(Riera et al., 2012). 
Recently, the yeast C. glabrata, usually commensal, 
has emerged as a common cause of serious life-threatening 
fungal infections largely owing to their low susceptibility 
to azole antifungals widely used in the treatment of these 
diseases (Silva et al., 2012). Consequently, recent guidance 
indicates the use of echinocandins as the first-choice drug 
for the treatment of systemic infections of C. glabrata 
(Silva et al., 2012; Pham et al., 2014). However, studies 
indicate that C. glabrata resistance to echinocandins is 
increasing (Pham et al., 2014).
Fluconazole-resistant isolates of C. glabrata have 
an increased possibility of being non-susceptible to 
echinocandins and vice versa. C. glabrata can present 
point mutations and changes in the chromosome 
structure, possibly related to mechanisms of adaptation 
to environmental changes. These genomic modifications 
may be a result of a defense mechanism making this 
fungus rapidly resistant to multiple drugs after limited 
exposure. For C. glabrata non-sensible to azoles and 
echinocandins, the only antifungal agent available is 
amphotericin B. Consequently, a two-fold problem 
arises because infections increase with aging, and 
amphotericin B is not well tolerated by elderly patients 
(Spreghini et al., 2012). 
Herein, we present a study of the induction of 
anidulafungin resistance in planktonic and sessile cells 




In total, 21 clinical strains of C. glabrata (RL37m, 
RL03m, RL09m, RL02, RL03, HCCG01, CG08, RL09, 
CG06, CG03, CG04, CG40039, RL12, CG18S, RL22, 
RL24, RL25, RL26, RL45, RL49, and RL51) belonging 
to the mycology collection of the Applied Mycology 
Laboratory, UFRGS, were used in this study. The clinical 
isolates were phenotypically identified by Vitek Yeast 
Biochemical Card (BioMerieux Vitek, Hazelwood, MO). 
In some tests, the characterized isolate CG40039 was 
included as a control.
Antifungal compounds
Stock solutions of anidulafungin (Ecalta®; Pfizer, 
São Paulo, Brazil) and fluconazole (Cristália®; São 
Paulo, Brazil) were prepared in sterile distilled water. For 
the experiments, the antifungal agents were diluted with 
RPMI 1640.
Biofilm formation assay on tracheal catheter 
material
The applied methodology is an adaptation of a 
procedure reported in the literature (Malheiros et al., 2010; 
Tondo et al., 2010). Initially, the strains were cultured on 
Sabouraud agar for 24 h at 35 ºC. Seven colonies were 
added to 2 mL TSB followed by incubation for 24 h at 
35 ºC. Further, 1- × 1-cm2 polyvinyl polychloride (PVC, 
Mark Med, number 12) catheter fragments were added 
to 9 mL peptone water containing 1 mL standardized 
inoculum in TSB followed by incubation for 96 h at 
35 °C. Then, the catheter fragments were washed thrice 
with peptone water to remove poorly adhered cells. The 
fragments were added to other flasks containing 50 mL 
peptone water, and the adhered cells were released by 
sonication at 40 KHz for 10 min, the resulting water 
following sonication was diluted (dilution factor, 10), 
allowing the determination of colony forming units (CFU), 
and 20 μL of each dilution was plated on Sabouraud agar. 
Next, the plates were incubated for 24 h at 35 °C, and the 
values of CFU/cm2 were determined. All counts were 
performed in triplicate. The best biofilm-forming strain 
cells obtained by this test were cultivated on Sabouraud 
agar and stored for further use.
Planktonic and sessile minimum inhibitory 
concentration (MIC) 
MICs of the planktonic and sessile cells of 
C. glabrata were determined in microplates by a broth 
microdilution method, as proposed by Clinical and 
Laboratory Standards Institute (CLSI), in accordance with 
protocol M27-A3 (CLSI, 2008), following the updates 
of document M27-S4 (CLSI, 2012). The antifungal was 
tested at concentrations of 0.0075−4.0 μg/mL. 
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Induction of anidulafungin resistance in 
planktonic and sessile cells and evaluation of its 
stability
This test was performed by exposing the strains 
to successively higher concentrations of antifungal, 
as described by Fekete-forgacs, Gyure, and Lenkey 
(2000), with slight modifications. One colony of 
each C. glabrata strain, anidulafungin-sensitive 
[≤ 0.12 µg/mL for anidulafungin was considered as 
susceptible and ≥0.5 µg/mL as resistant, M27-S4 (CLSI, 
2012)], was incubated with 10 mL RPMI 1640 containing 
4% glucose for 24 h at 35 °C. After centrifugation, 
supernatant was discarded, leaving only the yeast cells 
in the vials. Further, RPMI 1640 was added until a final 
absorbance of 0.1 (λ = 640 nm) was obtained. After 10-h 
incubation, the material was centrifuged, and supernatant 
was discarded; 10 mL anidulafungin was diluted with 
RPMI to the desired concentration (MIC/8). After 14-h 
incubation, the previous procedure was repeated three 
consecutive times but with a 24-h incubation interval. 
After the third incubation, 20 μL of each culture was 
grown on Sabouraud agar for 24 h. A sample of cells 
was subcultured for MIC determination and stored for 
further testing. After another round of centrifugation 
and discarding of supernatant, the antifungal was added 
at the MIC/8 concentration until the final absorbance 
of 0.1 was obtained. After 10-h incubation, the culture 
was centrifuged again, and supernatant was discarded. 
Then, 10 mL MIC/4 concentration of anidulafungin was 
added and incubated for 14 h, as described above. The 
experiment was repeated doubling the concentration of 
anidulafungin until the final concentration of 0.25 μg/mL 
was obtained for all strains.
Fluconazole cross-resistance detection
Fluconazole cross-resistance was assessed by MIC 
determination of anidulafungin-resistant strains and 
compared with MIC prior to the induction of in vitro 
resistance.
RESULTS
The biofilm formation assay demonstrated that all 
C. glabrata strains could form a biofilm on the tracheal 
catheter material (Table I). This screening for the 
identification of optimum biofilm formation indicated 
seven outstanding biofilm-forming strains (RL12, CG18S, 
CG40039, RL09m, RL22, RL25, and RL26), which were 
selected for the experiments of induction of anidulafungin 
resistance. These strains were selected based on the results 
that showed the highest colony count (CFU/cm2 and log).
MICs of the planktonic and sessile cells of 
C. glabrata determined by a broth microdilution method, 
as proposed by the CLSI, are presented in Table II. In 
general, the sessile cells presented slightly reduced 
susceptibility compared with the planktonic cells. 
MICs were in the range of <0.0075−0.03 μg/mL for the 
planktonic cells and 0.015−0.06 μg/mL for the sessile 
cells.
Following the induction of anidulafungin resistance 
against the sessile and planktonic forms of the C. glabrata 
strains, MICs were determined again. It was observed 
that six out of seven strains tested (86%) acquired strong 
anidulafungin resistance (Table II). Differences between 
MICs of the biofilm and planktonic cells after the induction 
of in vitro resistance were not noted, which was previously 
TABLE I - C. glabrata biofilm forming strains on tracheal 
catheter material expressed in colony-forming unit per cm2 






RL 37m 1,5x104 4,1
RL 03m 2,2x104 4,3
RL 09m* 7,5x104 4,8
RL 02 0,2x104 3,2
RL 03 0,2x104 3,2
HCCG 01 1,5x104 4,1
CG 08 1,5x104 4,1
RL 09 1,5x104 4,1
CG 06 0,2x104 3,2
CG 03 0,2x104 3,2
CG 04 0,2x104 3,2
CG 40039* 7,5x104 4,8
RL 12* 12,5x104 5,1
CG 18S* 12,5x104 5,1
RL 22* 7,5x104 4,8
RL 24 0,7x104 3,8
RL 25* 4,0x104 4,6
RL 26* 3,5x104 4,5
RL 45 1,5x104 4,1
RL 49 2,2x104 4,3
RL 51 1,5x104 4,1
* Stains selected to the induction experiments of resistance to 
anidulafungin
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verified. In addition, morphological changes (phenotypic 
switching) to non-susceptible C. glabrata strains were 
observed. Furthermore, after 30-day subculturing of the 
resistant strains in anidulafungin-free medium, MICs 
indicated that resistance was maintained for six strains. 
Moreover, the occurrence of cross-resistance 
to fluconazole was investigated by an MIC assay for 
anidulafungin-resistant C. glabrata strains. MICs 
were compared with anidulafungin-sensitive strains. 
Surprisingly, all strains with previous exposure to 
anidulafungin showed resistance to fluconazole 
(MIC ≥ 64 µg/mL; Table III). For the planktonic and 
sessile cells, very similar results were obtained.
DISCUSSION
According to protocol M27-A34 and considering the 
updates of document M27-S4 (CLSI, 2012), anidulafungin-
susceptible isolates present MICs ≤ 0.12 μg/mL. Notably, 
all selected strains were sensitive to the antifungal tested, 
in both their planktonic and sessile forms (Table II). In 
previous studies described by Pfaller and collaborators, 
only 3.8% of the isolates of C. glabrata obtained from 
Asia were resistant to anidulafungin, whereas none of the 
isolates from Latin America was non-susceptible to this 
antifungal (Pfaller et al., 2012, 2013). The sessile form of 
the strains was less or equally sensitive to anidulafungin 
when compared with the planktonic form (Table II), which 
corroborates the findings of Kucharikova et al. (2011), 
suggesting that C. glabrata biofilms formed in vitro or by 
animal models are resistant to azoles but are sensitive to 
echinocandins.
The induction of resistance resulted in strains 
strongly resistant to anidulafungin with MICs in the 
range of 1−2 μg/mL (Table II). Bordallo-Cardona and 
collaborators also obtained resistant C. glabrata strains 
TABLE II - Minimal inhibitory concentrations (MICs) of anidulafungin and phenotypes (Phen) of sessile and planktonic cells of 












RL 12 0.03/ S 1.0/ R 0.03/ S 1.0/ R
CG 18S < 0.0075/ S 2.0/ R 0.06/ S 2.0/ R
CG 40039 0.03/ S 2.0/ R 0.03/ S 2.0/ R
RL 09m 0.015/ S 0.03/ S 0.03/ S 0.03/ S
RL 22 < 0.0075/ S 2.0/ R 0.015/ S 2.0/ R
RL 25 0.015/ S 2.0/ R 0.03/ S 2.0/ R
RL 26 < 0.0075/ S 2.0/ R 0.03/ S 2.0/ R
 Phen* are expressed as susceptible (S) or resistant (R)
TABLE III - Minimal inhibitory concentrations (MICs) of fluconazole and phenotypes (Phen) of sessile and planktonic cells of 
C. glabrata before and after induction of resistance to anidulafungin
Candida glabrata 
strain









CG40039 16/ SDD >64/ R 16/ SDD >64/ R
RL12 32/ SDD >64/ R 8/ SDD >64/ R
RL09m 32/ SDD 64/ R 4/ SDD >64/ R
RL22 1/ SDD >64/ R 32/ SDD >64/ R
RL25 32/ SDD >64/ R 32/ SDD >64/ R
RL26 4/ SDD >64/ R 4/ SDD >64/ R
CG18S 4/ SDD >64/ R 4/ SDD >64/ R
Phen* are expressed as susceptible-dose dependent (SDD) or resistant (R).
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after in vitro exposure to higher concentrations of 
micafungin and anidulafungin. In their experiment, MICs 
of Sabouraud agar plates containing these antifungals 
were 0.06−4 μg/mL (micafungin) and 1−4 μg/mL 
(anidulafungin) (Bordallo-Cardona et al., 2017).
Biofilm cells have antimicrobial resistance 
characteristics that confer tolerance to drug concentrations 
1000 times higher than the MIC determined for 
planktonic cells (D’enfert, Janbon, 2016). Thus, as a final 
result of the induction of in vitro resistance, larger MICs 
were expected for the sessile than for the planktonic 
cells. Surprisingly, this behavior was not observed in 
the present experiments (Table II). It was verified that 
biofilm and planktonic cells present the same MIC, not 
maintaining their susceptibility observed prior to the 
induction of in vitro resistance.
To analyze the stability of the developed resistance, 
the strains were harvested for 30 days with antifungal-
free Sabouraud agar. The results showed the preservation 
of resistance for all strains. Previously, Borst and 
coworkers (2005) also demonstrated the maintenance of 
acquired resistance to C. glabrata for at least 4 months 
after the removal of fluconazole. This result is clinically 
relevant and worrying because, once resistant, these 
cells will continue to express resistance genes for an 
extended period. Eventually, antifungal treatment 
becomes ineffective, making the introduction of a second 
therapeutic drug necessary. In addition, there is a risk of 
the dissemination of resistance of these isolates to other 
patients, further limiting therapeutic options.
In addition, morphological changes (phenotypic 
switching) observed in the C. glabrata strains can be 
related to resistance. Phenotypic switching enables 
microorganisms to undergo rapid microevolution and 
to adapt to a constantly changing microenvironment. In 
addition, it facilitates pathoadaptation into the host (Jain, 
Hasan, Fries, 2008). Similar to C. albicans, C. glabrata 
is capable of expressing different cellular phenotypes in 
colonizing populations, including phenotype irregular 
wrinkle (Lachke et al., 2002). To C. albicans, this 
effect was correlated to high-level antifungal resistance, 
indicating that morphological change may have an effect 
on drug sensitivity (Vargas et al., 2000). 
According to the CLSI, the C. glabrata strains 
having MICs ≥ 64 μg/mL are considered resistant to 
fluconazole; meanwhile, C. glabrata presenting MICs ≤ 
32 μg/mL are classified as sensitive in a dose-dependent 
manner. It was observed that prior to the induction of 
in vitro resistance, the planktonic and sessile forms of 
the strains were all sensitive to fluconazole in a dose-
dependent manner with MICs in the range of 1−32 
μg/mL (Table III). Interestingly, after the induction of 
anidulafungin resistance, this dose-dependent sensitivity 
to fluconazole was not maintained, making these strains 
resistant to this antifungal.
Fluconazole resistance has been associated with 
non-susceptibility to echinocandins in other studies 
(Pfaller et al., 2012, 2013). Azole resistance often 
results from the overexpression of efflux pumps, which 
are not related to echinocandin resistance. However, 
C. glabrata has a unique ability to sequentially acquire and 
express mutations responsible for conferring resistance. 
Therefore, it is possible that previous treatments with 
fluconazole exert selective pressure, resulting in changes 
in the genome of the pathogen even in the absence of 
evident fluconazole resistance. These microorganisms 
may persist as colonizers in patients and emerge as 
resistant to echinocandins after subsequent exposure 
to antifungal agents (Vallabhaneni et al., 2015). In our 
study, the opposite was observed: the emergence of 
fluconazole-resistant strains after previous exposure to 
anidulafungin. This observation was also previously 
reported (Alexander et al., 2013), suggesting that previous 
therapy with azoles or echinocandins is predictive of 
resistance to both classes of antifungals. 
Finally, most of the sessile cells had slightly reduced 
susceptibility when compared with the planktonic cells. 
The strains subjected to the induction test to anidulafungin 
resistance also developed strong anidulafungin and 
fluconazole resistances, corroborating reports of cross-
resistance between the classes of azoles and echinocandins. 
Clinically, this cross-resistance could lead to therapeutic 
failure in fluconazole-treated patients who were previously 
exposed to subinhibitory concentrations of anidulafungin 
for extended periods. 
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